InSilico Medicine

InSilico Medicine is a Hong Kong-based artificial intelligence company with R&D and management resources in the United States, Belgium, Russia, the United Kingdom, Taiwan, and mainland China through hackathons and competitions. InSilico Medicine is committed to developing high-performance AI platforms for drug discovery to treat cancer and other diseases. InSilico Medicine is currently developing an end-to-end pipeline covering every step of drug discovery, clinical trial analysis, and digital medicine while pursuing internal drug discovery programs for cancer, skin diseases, fibrosis, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), diabetes, sarcopenia, and aging. Through its collaboration with Life Extension, the company has launched a series of nutraceuticals using advanced bioinformatics technologies and deep learning methods for compound formulation. Additionally, InSilico Medicine offers a range of consumer-facing applications, including Young.AI.